BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Rim CH, Seong J. Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines. Radiat Oncol J. 2016;34:160-167. [PMID: 27730805 DOI: 10.3857/roj.2016.01970] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
2 Yoon SM. External Beam Radiotherapy for Hepatocellular Carcinoma: a Review of the Current Guidelines in the East and the West. J Liver Cancer 2021;21:25-33. [DOI: 10.17998/jlc.21.1.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Han KH, Park JY. Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. J Gastroenterol Hepatol 2010;25:1023-5. [PMID: 20594213 DOI: 10.1111/j.1440-1746.2010.06359.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
4 Yoon HI, Koom WS, Lee IJ, Jeong K, Chung Y, Kim JK, Lee KS, Han KH, Seong J. The significance of ICG-R15 in predicting hepatic toxicity in patients receiving radiotherapy for hepatocellular carcinoma. Liver Int. 2012;32:1165-1171. [PMID: 22435801 DOI: 10.1111/j.1478-3231.2012.02784.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
5 Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 2013;8:e63864. [PMID: 23737955 DOI: 10.1371/journal.pone.0063864] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 8.7] [Reference Citation Analysis]
6 Kim YH, Kim do Y. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know. Oncology. 2013;84 Suppl 1:34-39. [PMID: 23428856 DOI: 10.1159/000345887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
7 Kim BK, Ahn SH, Seong JS, Park JY, Kim do Y, Kim JK, Lee do Y, Lee KH, Han KH. Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int. 2011;31:369-376. [PMID: 21083802 DOI: 10.1111/j.1478-3231.2010.02368.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 3.4] [Reference Citation Analysis]
8 Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. Jpn J Clin Oncol. 2012;42:721-729. [PMID: 22689916 DOI: 10.1093/jjco/hys082] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
9 Kim JY, Chung SM, Choi BO, Kay CS. Hepatocellular carcinoma with portal vein tumor thrombosis: Improved treatment outcomes with external beam radiation therapy. Hepatol Res 2011;41:813-24. [PMID: 21696524 DOI: 10.1111/j.1872-034X.2011.00826.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
10 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
11 Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol. 2009;15 Suppl 6:S50-S59. [PMID: 20037280 DOI: 10.3350/kjhep.2009.15.s6.s50] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
12 Chen CT, Liu TH, Shao YY, Liu KL, Liang PC, Lin ZZ. Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma. Int J Mol Sci 2021;22:12880. [PMID: 34884684 DOI: 10.3390/ijms222312880] [Reference Citation Analysis]
13 Ohri N, Dawson LA, Krishnan S, Seong J, Cheng JC, Sarin SK, Kinkhabwala M, Ahmed MM, Vikram B, Coleman CN, Guha C. Radiotherapy for Hepatocellular Carcinoma: New Indications and Directions for Future Study. J Natl Cancer Inst. 2016;108. [PMID: 27377923 DOI: 10.1093/jnci/djw133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
14 Jeon MY, Lee HW, Kim SU, Kim BK, Park JY, Kim DY, Han K, Ahn SH. Feasibility of dynamic risk prediction for hepatocellular carcinoma development in patients with chronic hepatitis B. Liver Int 2018;38:676-86. [DOI: 10.1111/liv.13583] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
15 Yoon HI, Lee IJ, Han KH, Seong J. Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2014;140:1595-605. [PMID: 24809934 DOI: 10.1007/s00432-014-1697-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
16 Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int. 2014;34:313-321. [PMID: 23895043 DOI: 10.1111/liv.12274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
17 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
18 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
19 Chen P, Furuse J, Han K, Hsu C, Lim H, Moon H, Qin S, Ye S, Yeoh E, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion: HCC clinical trials in Asia. Liver International 2010;30:1427-38. [DOI: 10.1111/j.1478-3231.2010.02292.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
20 Cho Y, Kim JW, Kim JK, Lee KS, Lee JI, Lee HW, Lee KH, Joo SM, Lim JH, Lee IJ. Phase I Radiation Dose-Escalation Study to Investigate the Dose-Limiting Toxicity of Concurrent Intra-Arterial Chemotherapy for Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1612. [PMID: 32570869 DOI: 10.3390/cancers12061612] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Park MS, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Seong J. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol. 2013;71:165-173. [PMID: 23079897 DOI: 10.1007/s00280-012-1993-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
22 Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245-1255. [PMID: 22353262 DOI: 10.1016/s0140-6736(11)61347-0] [Cited by in Crossref: 2892] [Cited by in F6Publishing: 1689] [Article Influence: 289.2] [Reference Citation Analysis]
23 Lee HS, Choi GH, Choi JS, Kim KS, Han K, Seong J, Ahn SH, Kim DY, Park JY, Kim SU, Kim BK. Surgical Resection After Down-Staging of Locally Advanced Hepatocellular Carcinoma by Localized Concurrent Chemoradiotherapy. Ann Surg Oncol 2014;21:3646-53. [DOI: 10.1245/s10434-014-3652-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
24 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Zhang ZM, Guo JX, Zhang ZC, Jiang N, Zhang ZY, Pan LJ. Therapeutic options for intermediate-advanced hepatocellular carcinoma. World J Gastroenterol 2011;17:1685-9. [PMID: 21483627 DOI: 10.3748/wjg.v17.i13.1685] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
26 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
27 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
28 Byun HK, Kim HJ, Im YR, Kim DY, Han K, Seong J. Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma. Radiotherapy and Oncology 2019;133:1-8. [DOI: 10.1016/j.radonc.2018.12.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
29 Song JE, Jung KS, Kim DY, Song K, Won JY, Lee HW, Kim BK, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Int J Radiat Oncol Biol Phys 2017;99:396-406. [PMID: 28871990 DOI: 10.1016/j.ijrobp.2017.05.049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
30 Pérez-Romasanta LA, González-Del Portillo E, Rodríguez-Gutiérrez A, Matías-Pérez Á. Stereotactic Radiotherapy for Hepatocellular Carcinoma, Radiosensitization Strategies and Radiation-Immunotherapy Combination. Cancers (Basel) 2021;13:E192. [PMID: 33430362 DOI: 10.3390/cancers13020192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J. 2013;54:1178-1185. [PMID: 23918567 DOI: 10.3349/ymj.2013.54.5.1178] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
32 Lee JW, Oh JK, Chung YA, Na SJ, Hyun SH, Hong IK, Eo JS, Song BI, Kim TS, Kim do Y. Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy: A Multicenter Retrospective Cohort Study. J Nucl Med. 2016;57:509-516. [PMID: 26742711 DOI: 10.2967/jnumed.115.167338] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
33 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
34 Yang L, Xiao H, Yan L, Wang R, Huang Y, Xie Z, Jing X. Lactose targeting oxaliplatin prodrug loaded micelles for more effective chemotherapy of hepatocellular carcinoma. J Mater Chem B 2014;2:2097. [DOI: 10.1039/c3tb21709d] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
35 Aitken K, Hawkins M. The Role of Radiotherapy and Chemoradiation in the Management of Primary Liver Tumours. Clinical Oncology 2014;26:569-80. [DOI: 10.1016/j.clon.2014.05.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
36 Kim JW, Seong J, Park MS, Kim KS, Park YN, Han KH, Keum KC, Lee IJ. Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery: Radiotherapy for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2016;31:1619-27. [DOI: 10.1111/jgh.13334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, Lee WJ, Park SJ, Kim DY, Kim CM. Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol. 2014;190:806-814. [PMID: 24589917 DOI: 10.1007/s00066-014-0604-6] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
38 Yoon HI, Song KJ, Lee IJ, Kim do Y, Han KH, Seong J. Clinical Benefit of Hepatic Arterial Infusion Concurrent Chemoradiotherapy in Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Cancer Res Treat. 2016;48:190-197. [PMID: 25761480 DOI: 10.4143/crt.2014.276] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
39 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 4.5] [Reference Citation Analysis]
40 Lee IJ, Kim JW, Han KH, Kim JK, Kim KS, Choi JS, Park YN, Seong J. Concurrent chemoradiotherapy shows long-term survival after conversion from locally advanced to resectable hepatocellular carcinoma. Yonsei Med J 2014;55:1489-97. [PMID: 25323884 DOI: 10.3349/ymj.2014.55.6.1489] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
41 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
42 Han S, Choi HJ, Beom SH, Kim HR, Lee H, Lee JS, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Kim BK. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2021;147:3123-33. [PMID: 33893539 DOI: 10.1007/s00432-021-03632-4] [Reference Citation Analysis]
43 Lee IJ, Seong J. Radiosensitizers in Hepatocellular Carcinoma. Seminars in Radiation Oncology 2011;21:303-11. [DOI: 10.1016/j.semradonc.2011.05.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
44 Cha H, Yoon HI, Lee IJ, Koom WS, Han KH, Seong J. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res. 2013;54:1069-1077. [PMID: 23633620 DOI: 10.1093/jrr/rrt034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
45 Kim JK, Kim JW, Lee IJ, Joo SM, Lee KH, Cho ES, Yu JS, Jeon TJ, Kim Y, Lee JI, Lee KS. Factors affecting survival after concurrent chemoradiation therapy for advanced hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:133. [PMID: 28810886 DOI: 10.1186/s13014-017-0873-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Yoon HI, Seong J. Optimal Selection of Radiotherapy as Part of a Multimodal Approach for Hepatocellular Carcinoma. Liver Cancer 2016;5:139-51. [PMID: 27386432 DOI: 10.1159/000367762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Lee WC, Chou HS, Wu TJ, Lee CF, Hsu PY, Hsu HY, Wu TH, Chan KM. Down-regulation of metabolic proteins in hepatocellular carcinoma with portal vein thrombosis. Clin Proteomics 2017;14:29. [PMID: 28785178 DOI: 10.1186/s12014-017-9164-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
48 Chong JU, Choi GH, Han DH, Kim KS, Seong J, Han K, Choi JS. Downstaging with Localized Concurrent Chemoradiotherapy Can Identify Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Ann Surg Oncol 2018;25:3308-15. [DOI: 10.1245/s10434-018-6653-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
49 Lee S, Kim BK, Kim SU, Park Y, Chang S, Park JY, Kim do Y, Ahn SH, Chon CY, Han KH. Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma. PLoS One. 2013;8:e77240. [PMID: 24155932 DOI: 10.1371/journal.pone.0077240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
50 Seong J. Challenge and hope in radiotherapy of hepatocellular carcinoma. Yonsei Med J. 2009;50:601-612. [PMID: 19881961 DOI: 10.3349/ymj.2009.50.5.601] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
51 Kim BK, Kim DY, Byun HK, Choi HJ, Beom SH, Lee HW, Kim SU, Park JY, Ahn SH, Seong J, Han KH. Efficacy and Safety of Liver-Directed Concurrent Chemoradiotherapy and Sequential Sorafenib for Advanced Hepatocellular Carcinoma: A Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 2020;107:106-15. [PMID: 32084526 DOI: 10.1016/j.ijrobp.2020.01.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
52 Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol. 2011;26:1123-1132. [PMID: 21501224 DOI: 10.1111/j.1440-1746.2011.06745.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
53 Shin SH, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Liver stiffness-based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis. Liver Int. 2015;35:1054-1062. [PMID: 24930484 DOI: 10.1111/liv.12621] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
54 Shin HS, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Baatarkhuu O, Ahn SH. Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. J Gastroenterol Hepatol 2012;27:1528-34. [PMID: 22497450 DOI: 10.1111/j.1440-1746.2012.07145.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
55 Torimura T, Ueno T, Taniguchi E, Masuda H, Iwamoto H, Nakamura T, Inoue K, Hashimoto O, Abe M, Koga H, Barresi V, Nakashima E, Yano H, Sata M. Interaction of endothelial progenitor cells expressing cytosine deaminase in tumor tissues and 5-fluorocytosine administration suppresses growth of 5-fluorouracil-sensitive liver cancer in mice. Cancer Sci 2012;103:542-8. [PMID: 22151662 DOI: 10.1111/j.1349-7006.2011.02182.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
56 Yu JI, Park HC, Oh D, Noh JM, Jung SH, Kim HY, Shin SW, Cho SK, Sinn DH, Paik YH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Combination treatment of trans-arterial chemo-embolisation, radiotherapy and hyperthermia (CERT) for hepatocellular carcinoma with portal vein tumour thrombosis: Interim analysis of prospective phase II trial.Int J Hyperthermia. 2016;32:331-338. [PMID: 26915594 DOI: 10.3109/02656736.2016.1144895] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Yeoh KW, Prawira A, Saad MZB, Lee KM, Lee EMH, Low GK, Mohd Nasir MHB, Phua JH, Chow WWL, Lim IJH, Omar YB, Ho RZW, Le TBU, Vu TC, Soo KC, Huynh H. Vinorelbine Augments Radiotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E872. [PMID: 32260169 DOI: 10.3390/cancers12040872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Chun YH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Kim BK, Choi GH, Kim KS, Choi JS, Ahn SH. Prognostic value of the 7th edition of the AJCC staging system as a clinical staging system in patients with hepatocellular carcinoma. Eur J Cancer. 2011;47:2568-2575. [PMID: 21835608 DOI: 10.1016/j.ejca.2011.07.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
60 Han S, Lee HW, Park JY, Kim SU, Kim DY, Ahn SH, Han KH, Seong J, Won JY, Han DH, Kim BK. Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion. J Hepatocell Carcinoma 2020;7:403-12. [PMID: 33365287 DOI: 10.2147/JHC.S276528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
61 Lo YC, Hsu FC, Hung SK, Tseng KC, Hsieh YH, Lee MS, Tseng CW, Lin HY, Chen LC, Chiou WY. Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion. Ci Ji Yi Xue Za Zhi 2019;31:40-6. [PMID: 30692831 DOI: 10.4103/tcmj.tcmj_14_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
62 Jihye C, Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer 2012;1:216-25. [PMID: 24159586 DOI: 10.1159/000343836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
63 Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Park MS, Kim EH, Seong J, Lee DY, Han K. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int 2012;32:1120-7. [DOI: 10.1111/j.1478-3231.2012.02811.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 75] [Article Influence: 6.7] [Reference Citation Analysis]
64 Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442-453. [PMID: 22176468 DOI: 10.1111/j.1872-034x.2011.00943.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
65 Lee MH, Kim SU, Kim DY, Ahn SH, Choi EH, Lee KH, Lee DY, Seong J, Han K, Chon CY, Park JY. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma: Predictors in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2012;27:313-22. [DOI: 10.1111/j.1440-1746.2011.06867.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
66 Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK. Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. Int J Radiat Oncol Biol Phys. 2011;81:1343-1351. [PMID: 20934268 DOI: 10.1016/j.ijrobp.2010.07.1986] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
67 Zhang Z, Yin J, Zhang C, Liang N, Bai N, Chang A, Liu Y, Li Z, Tan X, Li N. Activating transcription factor 4 increases chemotherapeutics resistance of human hepatocellular carcinoma. Cancer Biol Ther. 2012;13:435-442. [PMID: 22338651 DOI: 10.4161/cbt.19295] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
68 Kim JY, Yoo EJ, Jang JW, Kwon JH, Kim KJ, Kay CS. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol 2013;8:15. [PMID: 23324259 DOI: 10.1186/1748-717X-8-15] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
69 Jiang W, Zeng Z. Radiation therapy for hepatocellular carcinoma: current status and perspectives from our experience. Oncol Rev 2009;3:257-64. [DOI: 10.1007/s12156-009-0025-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
70 Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys. 2013;87:22-32. [PMID: 23219567 DOI: 10.1016/j.ijrobp.2012.08.043] [Cited by in Crossref: 115] [Cited by in F6Publishing: 103] [Article Influence: 11.5] [Reference Citation Analysis]
71 Choi C, Choi GH, Kim TH, Tanaka M, Meng MB, Seong J. Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma. Liver Cancer 2014;3:405-16. [PMID: 26280002 DOI: 10.1159/000343861] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
72 Kim KH, Kim MS, Chang JS, Han KH, Kim do Y, Seong J. Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma. Liver Int. 2014;34:784-794. [PMID: 24330457 DOI: 10.1111/liv.12436] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
73 Lee JW, Hwang SH, Kim DY, Han KH, Yun M. Prognostic Value of FDG Uptake of Portal Vein Tumor Thrombosis in Patients With Locally Advanced Hepatocellular Carcinoma. Clin Nucl Med. 2017;42:e35-e40. [PMID: 27775940 DOI: 10.1097/rlu.0000000000001422] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
74 Yim HJ, Suh SJ, Um SH. Current management of hepatocellular carcinoma: An Eastern perspective. World J Gastroenterol 2015; 21(13): 3826-3842 [PMID: 25852267 DOI: 10.3748/wjg.v21.i13.3826] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.6] [Reference Citation Analysis]
75 Yu JI, Park JW, Park HC, Yoon SM, Lim DH, Lee JH, Lee HC, Kim SW, Kim JH. Clinical impact of combined transarterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: An external validation study. Radiother Oncol. 2016;118:408-415. [PMID: 26830695 DOI: 10.1016/j.radonc.2015.11.019] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
76 Choi SH, Seong J. Strategic Application of Radiotherapy for Hepatocellular Carcinoma. Clin Mol Hepatol. 2018; Epub ahead of print. [PMID: 29439305 DOI: 10.3350/cmh.2017.0073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
77 Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J. 2016;57:1276-1281. [PMID: 27401662 DOI: 10.3349/ymj.2016.57.5.1276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
78 Yoo EJ, Shin HS, Kim SU, Joo DJ, Park JY, Choi GH, Kim DY, Ahn SH, Seong J, Koh MJ, Han KH, Chon CY. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2013;6:755-9. [PMID: 23836988 DOI: 10.2147/OTT.S45602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
79 Lee WH, Byun HK, Choi JS, Choi GH, Han DH, Joo DJ, Kim DY, Han KH, Seong J. Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria. Radiother Oncol 2020;152:1-7. [PMID: 32739317 DOI: 10.1016/j.radonc.2020.07.046] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
80 Kong XQ, Dong YP, Wu JX, He JY, Le YY, Du KX, Peng QQ, Li JL. High-biologically effective dose palliative radiotherapy for a tumor thrombus might improve the long-term prognosis of hepatocellular carcinoma: a retrospective study. Radiat Oncol 2017;12:92. [PMID: 28569169 DOI: 10.1186/s13014-017-0831-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Kim HY, Park JW, Nam BH, Kim HK, Choi JI, Kim TH, Kim HB, Kim CM. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011;26:1612-1618. [PMID: 21517968 DOI: 10.1111/j.1440-1746.2011.06751.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
82 Kim KA, Park MS, Ji HJ, Park JY, Han KH, Kim MJ, Kim KW. Diffusion and perfusion MRI prediction of progression-free survival in patients with hepatocellular carcinoma treated with concurrent chemoradiotherapy. J Magn Reson Imaging. 2014;39:286-292. [PMID: 24302545 DOI: 10.1002/jmri.24161] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
83 Galun D, Srdic-Rajic T, Bogdanovic A, Loncar Z, Zuvela M. Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies. J Hepatocell Carcinoma 2017;4:93-103. [PMID: 28744453 DOI: 10.2147/JHC.S106529] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 5.6] [Reference Citation Analysis]
84 Uchikawa S, Kawaoka T, Aikata H, Kodama K, Nishida Y, Inagaki Y, Hatooka M, Morio K, Nakahara T, Murakami E, Hiramatsu A, Tsuge M, Imamura M, Kawakami Y, Chayama K. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. Hepatol Res 2018;48:814-20. [PMID: 29682855 DOI: 10.1111/hepr.13180] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
85 Klein J, Dawson LA, Tran TH, Adeyi O, Purdie T, Sherman M, Brade A. Metabolic syndrome-related hepatocellular carcinoma treated by volumetric modulated arc therapy. Curr Oncol 2014;21:e340-4. [PMID: 24764717 DOI: 10.3747/co.21.1756] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
86 Kim DY, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig Dis 2012;30:598-602. [PMID: 23258101 DOI: 10.1159/000343088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 63] [Article Influence: 1.2] [Reference Citation Analysis]
87 Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115:428-436. [PMID: 19107763 DOI: 10.1002/cncr.24029] [Cited by in Crossref: 108] [Cited by in F6Publishing: 112] [Article Influence: 8.3] [Reference Citation Analysis]
88 Lee YK, Kim SU, Kim do Y, Ahn SH, Lee KH, Lee do Y, Han KH, Chon CY, Park JY. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013;13:5. [PMID: 23282286 DOI: 10.1186/1471-2407-13-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
89 Massabeau C, Marchand V, Zefkili S, Servois V, Campana F, Giraud P. Early experience of helical tomotherapy for hepatobiliary radiotherapy. Case Reports Hepatol 2011;2011:545267. [PMID: 25954545 DOI: 10.1155/2011/545267] [Reference Citation Analysis]
90 Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim do Y, Ahn SH, Tak WY. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepatol. 2014;29:1463-1469. [PMID: 25273508 DOI: 10.1111/jgh.12542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
91 Cho IR, Lee HW, Song KJ, Kim BK, Kim SU, Kim DY, Ahn SH, Seong J, Han KH, Park JY. Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget 2017;8:79914-26. [PMID: 29108373 DOI: 10.18632/oncotarget.20321] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
92 Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, Bae SH, Tak WY. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology 2011;81 Suppl 1:134-40. [PMID: 22212947 DOI: 10.1159/000333276] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
93 Han K, Kim JH, Ko GY, Gwon DI, Sung KB. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review. World J Gastroenterol 2016; 22(1): 407-416 [PMID: 26755886 DOI: 10.3748/wjg.v22.i1.407] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 6.2] [Reference Citation Analysis]
94 Fujino H, Kimura T, Aikata H, Miyaki D, Kawaoka T, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K, Chayama K. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res. 2015;45:607-617. [PMID: 25052365 DOI: 10.1111/hepr.12392] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
95 Lee IJ, Seong J, Koom WS, Kim YB, Jeon BC, Kim JH, Han KH. Selection of the Optimal Radiotherapy Technique for Locally Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology 2011;41:882-9. [DOI: 10.1093/jjco/hyr053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
96 Cheng JW, Lv Y. New progress of non-surgical treatments for hepatocellular carcinoma. Med Oncol 2013;30:381. [PMID: 23292867 DOI: 10.1007/s12032-012-0381-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
97 Kim BK, Kang WJ, Kim JK, Seong J, Park JY, Kim DY, Ahn SH, Lee DY, Lee KH, Lee JD, Han KH. 18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma. Cancer. 2011;117:4779-4787. [PMID: 21469082 DOI: 10.1002/cncr.26099] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 3.6] [Reference Citation Analysis]
98 Park HC, Yu JI, Cheng JC, Zeng ZC, Hong JH, Wang ML, Kim MS, Chi KH, Liang PC, Lee RC, Lau WY, Han KH, Chow PK, Seong J. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. Liver Cancer. 2016;5:162-174. [PMID: 27493892 DOI: 10.1159/000367766] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
99 Chong JU, Choi JS. ASO Author Reflections: Identifying Optimal Surgical Candidates in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Ann Surg Oncol 2019;26:551-2. [PMID: 30565038 DOI: 10.1245/s10434-018-7018-0] [Reference Citation Analysis]
100 Onishi H, Nouso K, Nakamura S, Katsui K, Wada N, Morimoto Y, Miyahara K, Takeuchi Y, Kuwaki K, Yasunaka T. Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion. Hepatol Int. 2015;9:105-112. [PMID: 25788384 DOI: 10.1007/s12072-014-9592-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
101 Kim DY. Which treatment modality should we choose for advanced hepatocellular carcinoma? Korean J Hepatol 2010;16:353-4. [PMID: 21415577 DOI: 10.3350/kjhep.2010.16.4.353] [Reference Citation Analysis]
102 Lee DS, Seong J. Radiotherapeutic options for hepatocellular carcinoma with portal vein tumor thrombosis. Liver Cancer 2014;3:18-30. [PMID: 24804174 DOI: 10.1159/000343855] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
103 Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, Tengg-kobligk HV, Candinas D, Dufour J. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. Annals of Hepatology 2016;15:82-90. [DOI: 10.5604/16652681.1184233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
104 Byun HK, Chung SY, Kim KJ, Seong J. Role of Interleukin-7 in the Development of and Recovery from Radiation-Induced Lymphopenia: A Post-hoc Analysis of a Prospective Cohort. Cancer Res Treat 2021. [PMID: 33540496 DOI: 10.4143/crt.2020.1053] [Reference Citation Analysis]
105 Eom BW, Lee JH, Lee JS, Kim MJ, Ryu KW, Choi IJ, Cho SJ, Lee JY, Rhee J, Nam BH, Kim YW. Survival analysis of gastric cancer patients with tumor thrombus in the portal vein. J Surg Oncol 2012;105:310-5. [PMID: 21898415 DOI: 10.1002/jso.22083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
106 Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. J Radiat Res 2014;55:113-20. [PMID: 23772086 DOI: 10.1093/jrr/rrt082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]